NCT04718480View on ClinicalTrials.gov

Fluvoxamine Administration in Moderate SARS-CoV-2 (COVID-19) Infected Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

November 27, 2020

Primary Completion Date

March 15, 2022

Study Completion Date

May 31, 2022

Conditions
Covid19
Interventions
DRUG

Placebo

po placebo tablets

DRUG

Fluvoxamine

po fluvoxamine tablets

Trial Locations (4)

1097

Dél-pesti Centrumkórház, Budapest

4032

Debreceni Egyetem Kenézy Gyula Kórház Infektológia, Debrecen

H-1083

Semmelweis Egyetem Pulmonológiai Klinika, Budapest

H-1121

Országos Korányi Pulmonológiai Intézet, Budapest

All Listed Sponsors
lead

SigmaDrugs Research Ltd.

INDUSTRY

NCT04718480 - Fluvoxamine Administration in Moderate SARS-CoV-2 (COVID-19) Infected Patients | Biotech Hunter | Biotech Hunter